Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas-Reference-Cited by-同舟云学术

Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas

Published:2008-03-11 Issue:5 Volume:8 Page:357-363
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Filopanti M,Barbieri A M,Angioni A R,Colao A,Gasco V,Grottoli S,Peri A,Baglioni S,Fustini M F,Pigliaru F,Monte P D,Borretta G,Ambrosi B,Jaffrain-Rea M L,Gasperi M,Brogioni S,Cannavò S,Mantovani G,Beck-Peccoz P,Lania A,Spada A

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj20081.pdf

Reference34 articles.

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613–619.

2. Gillam MP, Molitch ME, Lombardi G, Colao A . Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485–534.

3. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500–509.

4. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine resistant prolactinomas. Neuroendocrinol 1994; 60: 314–322.

5. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A . Alteration of Gα subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 1996; 8: 737–746.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19/FGFR4/PRL;Journal of Endocrinological Investigation;2024-06-26

2. Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment;Frontiers in Endocrinology;2024-02-02

3. Approach to the Patient With Prolactinoma;The Journal of Clinical Endocrinology & Metabolism;2023-03-28

4. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance;The Journal of Clinical Endocrinology & Metabolism;2023-01-13

5. Microwaves as Diagnostic Tool for Pituitary Tumors: Preliminary Investigations;Electronics;2022-05-18